- Home
- AUST vs ANTX Comparison
AUST vs ANTX Comparison
Compare AUST & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | ANTX |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 30.1M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AUST | ANTX |
|---|---|---|
| Price | $1.78 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 98.0K | 58.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $1.01 |
| 52 Week High | $2.94 | $1.55 |
Technical Indicators
Market Signals| Indicator | AUST | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 56.82 |
| Support Level | $1.75 | $1.12 |
| Resistance Level | $2.15 | $1.23 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 39.45 | 77.27 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.